We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
-4.19%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.06%
5 Year Est. Return
+670.57%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
-$63.6M
Cap. Flow
-$14.6M
Cap. Flow %
-1.4%
Top 10 Hldgs %
44.54%
Holding
900
New
268
Increased
133
Reduced
141
Closed
310

Top Buys

Rank Stock Value
1
SLVM icon
Sylvamo
SLVM
+$64.9M
2
ARKK icon
ARK Innovation ETF
ARKK
+$54.7M
3
FULC icon
Fulcrum Therapeutics
FULC
+$48.9M
4
RIVN icon
Rivian
RIVN
+$32.4M
5
STOK icon
Stoke Therapeutics
STOK
+$22.5M

Top Sells

Rank Stock Value
1
QQQ icon
Invesco QQQ Trust
QQQ
+$143M
2
IPOF
Social Capital Hedosophia Holdings Corp. VI
IPOF
+$49M
3
CCVI
Churchill Capital Corp VI
CCVI
+$34.2M
4
AMD icon
Advanced Micro Devices
AMD
+$27.5M
5
CLDX icon
Celldex Therapeutics
CLDX
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 39.85%
2 Financials 15.44%
3 Materials 6.54%
4 Consumer Discretionary 6.02%
5 Industrials 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FULC icon
1
Fulcrum Therapeutics
FULC
$239M
$81.7M 7.86%
+3,453,371
New +$48.9M
ARKK icon
2
ARK Innovation ETF
ARKK
$5.64B
$67.9M 6.54%
1,025,000
+775,000
+310% +$54.7M
SLVM icon
3
Sylvamo
SLVM
$1.49B
$65.1M 6.26%
+1,955,000
New +$64.9M
ESTA icon
4
Establishment Labs
ESTA
$2.72B
$56.1M 5.4%
832,187
+21,500
+3% +$1.26M
FTAI icon
5
FTAI Aviation
FTAI
$21.1B
$38.3M 3.68%
1,740,647
-471,068
-21% -$10.5M
SMFG icon
6
Sumitomo Mitsui Financial
SMFG
$164B
$35.6M 3.43%
5,676,605
-300,000
-5% -$2.14M
RLMD icon
7
Relmada Therapeutics
RLMD
$557M
$31.4M 3.02%
1,164,361
+1,014,587
+677% +$21M
ACET icon
8
Adicet Bio
ACET
$85.2M
$30M 2.88%
+93,753
New +$21.6M
STOK icon
9
Stoke Therapeutics
STOK
$1.8B
$29.9M 2.88%
1,420,530
+1,125,105
+381% +$22.5M
RIVN icon
10
Rivian
RIVN
$22B
$26.8M 2.58%
+532,300
New +$32.4M
PMVP icon
11
PMV Pharmaceuticals
PMVP
$59.2M
$26.3M 2.53%
+1,261,529
New +$22.3M
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$25.5M 2.45%
3,732,778
– –
APYX icon
13
Apyx Medical
APYX
$173M
$17.2M 1.66%
2,634,003
+732,000
+38% +$7.21M
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.79B
$17.1M 1.65%
722,575
+719,397
+22,637% +$20.3M
IPOF
15
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
$17M 1.64%
1,685,351
-4,863,742
-74% -$49M
SCPL
16
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
$16.8M 1.62%
1,299,219
+1,298,196
+126,901% +$16.4M
RCKT icon
17
Rocket Pharmaceuticals
RCKT
$340M
$15.9M 1.53%
1,000,000
– –
ARKK icon
18
PUT
ARK Innovation ETF
ARKK
$5.64B
$15.6M 1.5%
1,025,000
+760,000
+287% +$53.6M
HCVIU
19
DELISTED
Hennessy Capital Investment Corp. VI Unit
HCVIU
$14.8M 1.43%
1,500,000
– –
PEGR
20
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
$14.6M 1.4%
1,500,000
-1,500,000
-50% -$14.5M
IMUX icon
21
Immunic
IMUX
$190M
$14.2M 1.37%
125,715
+100,129
+391% +$11.6M
PSTH
22
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
$14M 1.34%
702,000
+300,000
+75% +$5.95M
CTLP
23
DELISTED
Cantaloupe
CTLP
$13.8M 1.33%
2,038,479
-1,864,985
-48% -$14.2M
ET icon
24
Energy Transfer Partners
ET
$70.1B
$12.9M 1.24%
1,155,000
-1,081,536
-48% -$10.7M
INVZ icon
25
Innoviz Technologies
INVZ
$95M
$12.2M 1.18%
3,383,325
+133,463
+4% +$533K
1
2 3 4 5

Similar funds

CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
PWLP
Prio Wealth Limited Partnership Boston, Massachusetts $3.41B AUM 44.09% 1-Year Est. Return
FPCG
Fort Pitt Capital Group Pittsburgh, Pennsylvania $3.55B AUM 34.86% 1-Year Est. Return
SI
Scout Investments Kansas City, Missouri $3.8B AUM 45.91% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return

Cowen and Company's Q1 2022 Portfolio in Review

As of Q1 2022, Cowen and Company held 900 positions worth $1.04B, down 5.8% from $1.1B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cowen and Company's Q1 2022 filing shows 268 new, 133 increased, 141 reduced and 310 closed positions. Its largest new stake was Sylvamo: 1,955,000 shares worth $65.1M. The largest sale was Invesco QQQ Trust, an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 26% a quarter earlier, followed by Financials and Materials.

  • Cowen and Company's largest Q1 2022 buy was Sylvamo: 1,955,000 shares worth $65.1M.
  • Cowen and Company added most to ARK Innovation ETF in Q1 2022, an estimated $54.7M increase.
  • Cowen and Company's biggest Q1 2022 reduction was Invesco QQQ Trust, cutting an estimated $143M.
  • Cowen and Company fully exited Churchill Capital Corp VI in Q1 2022, selling an estimated $34.2M.
  • Cowen and Company's ten largest holdings make up 45% of its $1.04B portfolio in Q1 2022.
  • Cowen and Company opened 268 new positions and closed 310 in Q1 2022.
  • Cowen and Company's portfolio value fell 5.8% quarter-over-quarter to $1.04B.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.